By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Poxel SAS 

200 avenue Jean Jaures

Lyon    69007  France
Phone: 33-4-37-372010 Fax: 33-4-37-708815



Company News
Poxel SAS Announces Positive Results For Thorough QT Safety Clinical Study Of Imeglimin 3/21/2017 6:53:41 AM
Poxel SAS Announces Appointment Of Christophe Arbet-Engels, MD, PhD, MBA, As Chief Medical Officer And EVP Late Development & Medical Affairs, Based In Boston 3/7/2017 8:28:15 AM
Poxel SAS Announces Fourth Quarter 2016 Financial Update 1/27/2017 8:21:47 AM
Poxel SAS Announces CFO Departure 12/22/2016 1:44:07 PM
Poxel SAS Announces Phase 1 Initiation Of EYP001 For The Treatment Of Chronic Hepatitis B Virus Infection By Licensing Partner Enyo Pharma 12/19/2016 11:46:03 AM
Poxel SAS Release: Ability To Delay Type 2 Diabetes Disease Progression By Preserving Beta Cell Mass Observed In New Imeglimin Data 12/5/2016 1:01:54 PM
Poxel SAS Presents New Data On Imeglimin And PXL770 At The European Association For The Study Of Diabetes Annual Meeting 9/15/2016 11:37:20 AM
Poxel SAS To Present At The 18th Annual Rodman & Renshaw Global Investment Conference September 11-13th, 2016 9/6/2016 12:48:53 PM
Poxel SAS To Present New Imeglimin And PXL770 Data At The 52nd European Association For The Study Of Diabetes Annual Meeting 9/6/2016 11:44:30 AM
Poxel SAS Closes a €26.5 Million Capital Increase 7/18/2016 10:33:27 AM